Skip to main content

Advertisement

Log in

High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass

Osteoporosis International Aims and scope Submit manuscript

Abstract

A recent large-scale study revealed that glucocorticoid treatment increased fracture risk, which occurred at a far smaller dose and by a shorter duration than previously thought. To study the underlying mechanism for the increased risk of fracture, we studied the early changes in bone mineral density (BMD) and body composition by dual energy X-ray absorptiometry (DXA) after initiating high-dose glucocorticoid treatment. High-dose glucocorticoid treatment was arbitrarily defined as daily doses of ≥40 mg of a predonisolone equivalent. The 33 patients enrolled in this study had not received glucocorticoid treatment before. Only 2 months of treatment resulted in substantial BMD loss, most markedly in the lumbar spine, followed by the femoral neck and total body, which suggests the preferential trabecular bone loss. Body composition was also greatly affected. Thus, 2-month treatment with glucocorticoid significantly reduced bone mineral content (BMC), lean body mass (LBM) and increased fat mass (FAT). Our results are likely to have some clinical relevance. First, BMD loss occurs quite rapidly after starting glucocorticoid treatment, and patients receiving glucocorticoid treatment should be more carefully monitored for their BMD. Second, LBM, which mainly represents muscle volume, decreases rapidly after initiating glucocorticoid treatment. Decreased LBM might be also responsible for the increased risk of fracture, since falling is a well-known risk factor for fracture, and patients receiving glucocorticoid treatment should also be evaluated for their body composition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, Kohler JA, Furst DE (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96:115–123

    Article  CAS  PubMed  Google Scholar 

  2. van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroid and risk of fractures. J Bone Miner Res 15:993–1000

    Article  PubMed  ADS  Google Scholar 

  3. van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787

    Article  PubMed  ADS  Google Scholar 

  4. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277–285

    Article  CAS  PubMed  MathSciNet  Google Scholar 

  5. Kanda F, Okuda S, Matsushita T, Takatani K, Kimura KI, Chihara K (2001) Steroid myopathy: pathogenesis and effects of growth hormone and insulin-like growth factor-I administration. Horm Res 56:S24–S28

    Article  Google Scholar 

  6. American College of Rheumatology Task Force on Osteoporosis Guidelines (1996) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arth Rheum 39:1791–1801

    Google Scholar 

  7. Pearson D, Miller CG (eds) (2002) Clinical trials in osteoporosis. Springer, Heidelberg Germany New York

  8. Bonnick SL, Lewis LA (2002) Bone densitometry for technologists. Humana Press, Totowa, NJ

  9. Canalis E, Giustina A (2001) Glucocorticoid-induced osteoporosis: summary of a workshop. J Clin Endocrinol Metab 86:5681–5685

    Article  CAS  PubMed  Google Scholar 

  10. Canalis E, Delany AM (2002). Mechanism of glucocorticoid action in bone. Ann NY Acad Sci 966:73–81

    Article  CAS  PubMed  Google Scholar 

  11. Luengo M, Picado C, Del Rio L, Guanabens N, Monsterrat JM, Setoain J (1991) Vertebral fractures in steroid dependent asthma and involutional osteoporosis. Thorax 46:803–806

    Article  CAS  PubMed  Google Scholar 

  12. Selby PL, Halsey JP, Adams KRH, Klimiuk P, Knight SM, Pal B, Stewart IM, Swinson DR (2000) Corticosteroids do not alter the threshold for vertebral fracture. J Bone Miner Res 15:952–956

    Article  CAS  PubMed  Google Scholar 

  13. Houtkooper LB, Going SB, Sproul J, Blew RM, Lohman TG (2000) Comparison of methods for assessing body-composition changes over 1 year in postmenopausal women. Am J Clin Nutr 72:401–406

    CAS  PubMed  Google Scholar 

  14. Vestergaard P, Olsen ML, Paaske Johnsen S, Rejnmark L, Toft Sorensen H, Mosekilde L. (2003) J Intern Med 254:486–493

    Article  CAS  PubMed  Google Scholar 

  15. Bone and Tooth Society, National Osteoporosis Society, Royal College of Physicians. (2002) Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. Royal College of Physicians, London

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Koshi Natsui.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Natsui, K., Tanaka, K., Suda, M. et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int 17, 105–108 (2006). https://doi.org/10.1007/s00198-005-1923-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-005-1923-3

Keywords

Navigation